Factors leading to discontinuation of biologic therapy in patients with severe asthma

Jared Silver,a GlaxoSmithKline, Research Triangle Park, NC, USAView further author information

, MD, Phd,

Michael Bogart,a GlaxoSmithKline, Research Triangle Park, NC, USAView further author information

, Pharmd,

Nestor A. Molfino,a GlaxoSmithKline, Research Triangle Park, NC, USAView further author information

, MD, Msc,

James Siddall,b Adelphi Real World, Bollington, UKView further author information

, BA,

Mark Small,b Adelphi Real World, Bollington, UKView further author information

, BSc,

Matt Hanson,b Adelphi Real World, Bollington, UKView further author information

, MSc &

Beth Hahn,a GlaxoSmithKline, Research Triangle Park, NC, USACorrespondence[email protected]
View further author information

, Phd show all

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

G. Dargentolle, M. Georges, G. Beltramo, C. Poisson & P. Bonniaud. (2024) Effets indésirables des biothérapies de l’asthme sévère. Revue des Maladies Respiratoires 41:5, pages 372-381.
Crossref

Andrea Bever, Jessica Dunne, Jenna Reynolds, Susan Waserman, Alan G. Kaplan, Andrew O’Keefe, Stacey McNeilly & Shelagh M. Szabo. (2024) Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma. Advances in Therapy 41:4, pages 1401-1418.
Crossref

Martin Desrosiers, Zuzana Diamant, Paolo Castelnuovo, Peter W. Hellings, Joseph K. Han, Anju T. Peters, Jared Silver, Steven G. Smith, Abigail Fuller, Ana R. Sousa, Robert H. Chan & Philippe Gevaert. (2023) Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up. International Forum of Allergy & Rhinology 14:1, pages 18-31.
Crossref

Jiani Chen, Huan Wang, Chen Zhang, Le Shi, Qianqian Zhang, Xiaole Song, Dehui Wang, Li Hu, Hongmeng Yu & Xicai Sun. (2023) Comparative short‐term efficacy of endoscopic sinus surgery and biological therapies in chronic rhinosinusitis with nasal polyps: A network meta‐analysis. Clinical and Translational Allergy 13:6.
Crossref

Vinay K. Rathi, George A. Scangas, Ralph B. Metson, Roy Xiao, Leonce Nshuti & Stacie B. Dusetzina. (2022) Out‐of‐pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population. International Forum of Allergy & Rhinology 12:10, pages 1295-1298.
Crossref

Cristiano Caruso, Paolo Cameli, Elena Altieri, Maria Aliani, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Giorgio Walter Canonica, Stefano Centanni, Maria D’Amato, Stefano Del Giacco, Fausto De Michele, Elide Anna Pastorello, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Marco Caminati, Alessandra Vultaggio, Alessandro Zullo, Sara Rizzoli, Silvia Boarino, Gianfranco Vitiello, Francesco Menzella & Fabiano Di Marco. (2022) Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis. Frontiers in Medicine 9.
Crossref

R. Esnaud, W. Trzepizur, C. Chenivesse, G. Devouassoux & C. Taillé. (2022) Biothérapies dans l’asthme : comment s’y retrouver ?. Revue des Maladies Respiratoires Actualités 14:1, pages 1S96-1S99.
Crossref

Factors leading to discontinuation of biologic therapy in patients with severe asthma

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Factors leading to discontinuation of biologic therapy in patients with severe asthma

Citations (7)

Articles from other publishers (7)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date